Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.VRML · Entity 7871 | SVP Finance & CAO | March 23, 2017 | March 27, 2017 |
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Chief Financial Officer | April 17, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date March 23, 2017 · Filed March 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2027-03-23 | Direct | 75,000 |
Reported balance
After 2017-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-23 · Grant · Acquired 75,000 · Balance 75,000 F1: The option vests in four equal annual installments beginning on March 23, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal annual installments beginning on March 23, 2018.
FILANA THERAPEUTICS, INC.
Report date April 17, 2025 · Filed April 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2035-04-17 | Direct | 100,000 |
Reported balance
After 2025-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-17 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2025 Filed Apr 21, 2025 20:51 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001437749-25-012557 · rdgdoc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-04-17 F1 · derivative.exercise_date: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on April 17, 2026. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-24-036546 · rdgdoc.xml · derivative · entry 4 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | SaleCommon Stock | 59,800 | $3.86 | $230,828.00 |
DisclosureSEC source: 0001437749-24-036546 · rdgdoc.xml · nonDerivative · entry 3 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 F1 · price: 1. The sale reported in column 4 is a weighted average price. The shares were sold in multiple open market transactions at prices ranging from $3.81 to $3.89 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | SaleCommon Stock | 2,000 | $3.82 | $7,640.00 |
DisclosureSEC source: 0001437749-24-036546 · rdgdoc.xml · nonDerivative · entry 2 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By limited liability corporation Disclosed balance after: 0 Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:16 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 50,000 | $1.18 | $59,000.00 |
DisclosureSEC source: 0001437749-24-036546 · rdgdoc.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 21:46 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $26.91 | $0.00 |
DisclosureSEC source: 0001437749-24-028784 · rdgdoc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-09-06 F1 · derivative.exercise_date: The stock option vests over 2 years, with 50% cliff vesting 1-year after grant date and the remaining 50% cliff vesting 2-years after grant date. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:53 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $22.10 | $0.00 |
DisclosureSEC source: 0001437749-24-018024 · rdgdoc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-20 F1 · derivative.exercise_date: The stock option vests over four (4) years at a rate of 1/48th each full month. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 20:21 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock Warrant · Derivative | 1,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001437749-24-012331 · rdgdoc.xml · derivative · entry 5 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,920 Underlying: Common Stock · 1,500 shares Expires 2024-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying_shares: Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised. Read SEC document |
| April 17, 2024 Filed Apr 17, 2024 20:21 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | Exercise / conversionCommon Stock | 1,500 | $22.00 | $33,000.00 |
DisclosureSEC source: 0001437749-24-012331 · rdgdoc.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised. Read SEC document |
| January 03, 2024 Filed Apr 17, 2024 20:21 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantCommon Stock Warrant · Derivative | 800 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001437749-24-012331 · rdgdoc.xml · derivative · entry 4 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By limited liability corporation Disclosed balance after: 800 Underlying: Common Stock · 1,200 shares Expires 2024-05-07 F2 · shares: Represents warrants that were originally issued on January 3, 2024 as a pro-rata distribution to all holders of common shares. Each warrant entitles the holder to purchase one and one-half common shares at an exercise price of $33.00 per warrant. This distribution was exempt from immediate reporting under Section 16. Read SEC document |
| January 03, 2024 Filed Apr 17, 2024 20:21 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantCommon Stock Warrant · Derivative | 7,920 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001437749-24-012331 · rdgdoc.xml · derivative · entry 3 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,920 Underlying: Common Stock · 11,880 shares Expires 2024-05-07 F2 · shares: Represents warrants that were originally issued on January 3, 2024 as a pro-rata distribution to all holders of common shares. Each warrant entitles the holder to purchase one and one-half common shares at an exercise price of $33.00 per warrant. This distribution was exempt from immediate reporting under Section 16. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 22:36 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0001437749-23-027702 · rdgdoc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-10-03 F1 · derivative.exercise_date: The stock option vests over three (3) years at a rate of 1/36th each month. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 20:28 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 2,500 | $19.95 | $49,875.00 |
DisclosureSEC source: 0001069530-22-000037 · certent-form4.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 F1 · shares: Represents open market purchase of common stock for cash Read SEC document |
| August 05, 2021 Filed Feb 3, 2022 22:13 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001069530-22-000009 · certent-form5.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,300 F1 · price: Bona Fide Gift Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 21:25 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 2,000 | $7.04 | $14,080.00 |
DisclosureSEC source: 0001069530-20-000057 · certent-form4.xml · nonDerivative · entry 2 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Purchase by Schoen Family LLC. Reporting person is a member of the Schoen Family LLC. Disclosed balance after: 27,300 Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 21:25 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001069530-20-000057 · certent-form4.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,300 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.01 to $7.04 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. Read SEC document |
| December 19, 2019 Filed Dec 19, 2019 23:06 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 5,300 | $1.88 | $9,964.00 |
DisclosureSEC source: 0001069530-19-000063 · certent-form4.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 Read SEC document |
| May 14, 2019 Filed May 15, 2019 21:50 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | PurchaseCommon Stock | 10,000 | $1.06 | $10,600.00 |
DisclosureSEC source: 0001069530-19-000030 · certent-form4.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.05 to $1.06 per share. The reporting person undertakes to provide to Cassava, any security holder of Cassava or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:32 UTC | FILANA THERAPEUTICS, INC. PTIE · Entity 7294 | GrantCommon Stock (1) · Derivative | 50,000 | $1.18 Strike: $1.18 | $59,000.00 |
DisclosureSEC source: 0001069530-18-000062 · primary_doc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-10-31 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:06 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001532303-17-000002 · primary_doc.xml · derivative · entry 1 Schoen Eric · CIK 0001532303 · SVP Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 23, 2018. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:28 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseWarrants (Right to buy) · Derivative | 2,510 | $0.13 Strike: $1.80 | $313.75 |
DisclosureSEC source: 0001532303-17-000001 · primary_doc.xml · derivative · entry 2 Schoen Eric · CIK 0001532303 · Sr VP Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,510 Underlying: Common Stock · 2,510 shares Expires 2022-02-17 Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 21:28 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 | 3,347 | $1.40 | $4,685.80 |
DisclosureSEC source: 0001532303-17-000001 · primary_doc.xml · nonDerivative · entry 1 Schoen Eric · CIK 0001532303 · Sr VP Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,872 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.